Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy

Cancer Science

Volumn 100, Issue 1, 2009, Pages 54-61

  Maeshima, Akiko Miyagi ^a   Taniguchi, Hirokazu ^a   Nomoto, Junko ^a   Maruyama, Dai ^a   Kim, Sung Won ^a   Watanabe, Takashi ^a   Kobayashi, Yukio ^a   Tobinai, Kensei ^a   Matsuno, Yoshihiro ^a  

^a HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CD20 ANTIGEN; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER RELAPSE; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; COMBINATION CHEMOTHERAPY; DRUG MEGADOSE; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLICULAR LYMPHOMA; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MANTLE CELL LYMPHOMA; MONOTHERAPY; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; IMMUNOPHENOTYPING; LYMPHOMA, B-CELL; MALE; MIDDLE AGED;

EID: 58149310557     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.01005.x     Document Type: Article

References (35)

1. Reff ME, Carner K, Chambers KS et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-45.
2. Demidem A, Lam T, Alas S et al. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997; 12: 177-86.
3. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998; 91: 1644-52.
4. Cardarelli PM, Quinn M, Buckman D et al. Binding to CD20 by anti-B1 antibody or F(ab′)(2) is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother 2002; 51: 15-24.
5. Meeker T, Lewder J, Cteary ML et al. Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. N Eng J Med 1985; 312: 1658-65.
6. Kinoshita T, Nagai H, Murate T et al. CD20-negative relapse in B-cell lymphoma after treatment with rituximab. J Clin Oncol 1998; 16: 3916.
7. Davis TA, Czerwinski DK, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res 1999; 5: 611-15.
8. Schmitz K, Brugger W, Weiss B et al. Clonal selection of CD20-negative non-Hodgkin's lymphoma cells after treatment with anti-CD20 antibody rituximab. Br J Haematol 1999; 106: 571-2.
9. Foran JM, Norton AJ, Micallef IN et al. Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): A retrospective cohort analysis. Br J Haematol 2001; 114: 881-3.
10. Chu PG, Chen YY, Molina A et al. Recurrent B-cell neoplasms after Rituximab therapy: An immunophenotypic and genotypic study. Leuk Lymphoma 2002; 43: 2335-41.
11. Kennedy GA, Tey SK, Cobcroft R et al. Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: A retrospective review. Br J Haematol 2002; 119: 412-16.
12. Jilani I, O'Brien S, Manshuri T et al. Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood 2003; 102: 3514-20.
13. Goteri G, Olivieri A, Ranaldi M et al. Bone marrow histopathological and molecular changes of small B-cell lymphomas after rituximab therapy: comparison with clinical response and patients' outcome. Int J Immunopathol Pharmacol 2006; 19: 421-31.
14. Seliem RM, Freeman JK, Steingart RH et al. Immunophenotypic changes and clinical outcome in B-cell lymphomas treated with rituximab. Appl Immunohistochem Mol Morphol 2006; 14: 18-23.
15. Alovaro-Naranjo TA, Jaen-Martinez JJ, Guma-Padro JG et al. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: A new case report and review of the literature. Ann Hematol 2003; 82: 585-8.
16. Woehrer S, Streubel B, Chott A et al. Transformation of MALT lymphoma to pure plasma cell histology following treatment with the anti-CD20 antibody rituximab. Leuk Lymphoma 2005; 46: 1645-9.
17. Scaramucci L, Perrotti A, Niscola P et al. Hodgkin disease subsequent to follicular lymphoma on maintenance rituximab. Leuk Lymphoma 2007; 48: 1878-80.
18. Pijuan L, Vicioso L, Bellosillo B et al. CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: A molecular analysis using laser capture microdissection. Am J Surg Pathol 2005; 29: 1399-403.
19. Cragg MS, Bayne MC, Illidge TM et al. Apparent modulation of CD20 by rituximab: An alternative explanation. Blood 2004; 103: 3989-90.
20. Rawal YB, Nuovo GJ, Frambach GE et al. The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy. J Cutan Pathol 2005; 32: 616-21.
21. Takei K, Yamazaki T, Sawada U et al. Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines. Leuk Res 2006; 30: 625-31.
22. Tomita A, Hiraga J, Kiyoi H et al. Epigenetic regulation of CD20 protein expression in a novel B-cell lymphoma cell line, RRBL1, established from a patient treated repeatedly with rituximab-containing chemotherapy. Int J Hematol 2007; 86: 49-57.
23. Jazirehi AR, Vega MI, Bonavida B. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res 2007; 67: 1270-81.
24. Czuczman MS, Olejniczak S, Gowda A et al. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res 2008; 14: 1561-70.
25. Jaffe ES, Harris NL, Stein H et al. World Health Organization Classification of Tumours Pathology & Genetics: Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2001.
26. Sekiguchi N, Kobayashi Y, Yokota Y et al. Follicular lymphoma subgrouping by fluorescence in.situ hybridization analysis. Cancer Sci 2005; 96: 77-82.
27. Keith TA, Cousar JB, Glick AD et al. Plasmacytic differentiation in follicular center cell (FCC) lymphomas. Am J Clin Pathol 1985; 84: 283-90.
28. Vago JF, Hurtubise PE, Redden-Borowski MM et al. Follicular center-cell lymphoma with plasmacytic differentiation, monoclonal paraprotein, and peripheral blood involvement: Recapitulation of normal B-cell development. Am J Surg Pathol 1985; 9: 764-70.
29. Maeshima AM, Omatsu M, Nomoto J et al. Diffuse large B-cell lymphoma after transformation from low-grade follicular lymphoma: Morphological, immunohistochemical and FISH analyses. Cancer Sci 2008; 99: 1760-8.
30. Lenz G, Dreyling M, Hoster E et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005; 23: 1984-92.
31. Brauninger A, Hansmann ML, Strickler JG et al. Identification of common germinal-center B-cell precursors in two patients with both Hodgkin's disease and non-Hodgkin's lymphoma. N Eng J Med 1999; 340: 1239-47.
32. Marafioti T, Hummel M, Anagnostopoulos I et al. Classical Hodgkin's disease and follicular lymphoma originating from the same germinal center B cell. J Clin Oncol 1999; 17: 3804-9.
33. Micallef IN, Kirk A, Norton A et al. Peripheral T-cell lymphoma following rituximab therapy for B-cell lymphoma. Blood 1999; 93: 2427-8.
34. Tetreault S, Abler SL, Robbins B et al. Peripheral T-cell lymphoma after anti-CD20 antibody therapy. J Clin Oncol 1998; 16: 1635-7.
35. Cohen Y, Da'as N, Libstet D et al. Large-cell transformation of chronic lymphocytic leukemia and follicular lymphoma during or soon after treatment with fludarabine-rituximab-containing regimens: Natural history- or therapy-related complication? Eur J Haematol 2002; 68: 80-3.